CIK 0001133869 · Non-accelerated filer<br>Smaller reporting company
CAPRICOR THERAPEUTICS, INC.
Sign in to watch- Ticker
- CAPR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- (310) 358-3200
- Business address
- 10865 ROAD TO THE CURE, SUITE 150, SAN DIEGO, CA, 92121
- Former names
- Nile Therapeutics, Inc., SMI PRODUCTS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 97 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-06-05 | Litvack Frank Director | Grant or award · Stock Option (Right to Buy) | +280,935 | 280,935 | ||
| 2020-06-05 | COLLIER EARL M JR Director | Grant or award · Stock Option (Right to Buy) | +83,000 | 83,000 | ||
| 2020-06-05 | Musket David B Director | Grant or award · Stock Option (Right to Buy) | +109,000 | 109,000 | ||
| 2020-06-05 | Bergmann Anthony CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (Right to Buy) | +120,003 | 120,003 | ||
| 2020-02-12 | Marban Linda CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2020-02-12 | Marban Linda CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (Right to Buy) | +9,998 | 9,998 | ||
| 2020-02-12 | Marban Linda CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (Right to Buy) | +19,999 | 19,999 | ||
| 2020-02-12 | Marban Linda CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (Right to Buy) | +25,000 | 25,000 | ||
| 2020-02-12 | Marban Linda CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (Right to Buy) | +41,497 | 41,497 | ||
| 2020-02-12 | Marban Linda CHIEF EXECUTIVE OFFICER | Returned to the company · Stock Option (Right to Buy) | −25,000 | 0 | ||
| 2020-02-12 | Marban Linda CHIEF EXECUTIVE OFFICER | Returned to the company · Stock Option (Right to Buy) | −9,998 | 0 | ||
| 2020-02-12 | Marban Linda CHIEF EXECUTIVE OFFICER | Returned to the company · Stock Option (Right to Buy) | −19,999 | 0 | ||
| 2020-02-12 | Marban Linda CHIEF EXECUTIVE OFFICER | Returned to the company · Stock Option (Right to Buy) | −25,000 | 0 | ||
| 2020-02-12 | Marban Linda CHIEF EXECUTIVE OFFICER | Returned to the company · Stock Option (Right to Buy) | −41,497 | 0 | ||
| 2020-02-12 | Manzo Louis Director | Grant or award · Stock Option (Right to Buy) | +4,500 | 4,500 | ||
| 2020-02-12 | Manzo Louis Director | Grant or award · Stock Option (Right to Buy) | +2,550 | 2,550 | ||
| 2020-02-12 | Manzo Louis Director | Grant or award · Stock Option (Right to Buy) | +2,356 | 2,356 | ||
| 2020-02-12 | Manzo Louis Director | Grant or award · Stock Option (Right to Buy) | +3,000 | 3,000 | ||
| 2020-02-12 | Manzo Louis Director | Grant or award · Stock Option (Right to Buy) | +1,500 | 1,500 | ||
| 2020-02-12 | Manzo Louis Director | Grant or award · Stock Option (Right to Buy) | +1,401 | 1,401 |
Page 14 of 24 · 468 trades